Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders.
The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders.
Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field of neurology.
The seventh volume of this series is edited by Dr. Zareen Amtul (University of Windsor, Canada) along with series editor, Dr. Atta-ur-Rahman.
This latest volume features reviews that cover topics related to the treatment of neurodegenerative diseases (such as multiple sclerosis), tremors, epilepsy and stroke. The new volume highlights novel approaches to treating the mentioned conditions. The following list of chapters is featured in the volume
- Fatty Acid Amides as a New Potential Therapeutic Agent in Multiple Sclerosis
- Epileptic Seizures Detection Based on Non-Linear Characteristics Coupled with Machine Learning Techniques
- Hampering Essential Tremor Neurodegeneration in Essential Tremor: Present and Future Directions
- The Potential Therapeutic Role of the Melatoninergic System in Treatment of Epilepsy and Comorbid Depression
- Modeling Neurodegenerative Diseases Using Transgenic Model of Drosophila
- Genetic Basis in Stroke Treatment: Targets of Potent Inhibitors
More than 3 billion people worldwide lived with a neurological condition in 2021, new study reports